Literature DB >> 10942848

The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task.

R A Avery1, J S Franowicz, C Studholme, C H van Dyck, A F Arnsten.   

Abstract

Research indicates that norepinephrine enhances the working memory functions of the prefrontal cortex (PFC) through actions at post-synaptic, alpha-2A adrenoceptors. The current study examined the effects of the alpha-2A adrenoreceptor agonist, guanfacine (0.7 mg/kg, i.m.), compared to saline on SPECT measures of regional cerebral blood flow (rCBF) in monkeys performing a spatial working memory task. Animals were infused with the SPECT blood flow tracer, Tcm-99m ECD, through an indwelling intravenous catheter while performing the working memory task. Guanfacine treatment significantly improved cognitive performance of the working memory task, and significantly increased rCBF values in the dorsolateral PFC, the brain region most tightly associated with performance of spatial working memory tasks. In contrast, guanfacine had no significant effect on rCBF in the superior temporal cortex, an auditory association area unrelated to task performance. These data are consistent with the hypothesis that alpha-2A adrenoceptor stimulation preferentially enhances functioning of the PFC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942848     DOI: 10.1016/S0893-133X(00)00111-1

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  52 in total

Review 1.  The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder.

Authors:  Amy F T Arnsten
Journal:  Expert Rev Neurother       Date:  2010-10       Impact factor: 4.618

Review 2.  A neurochemical yin and yang: does serotonin activate and norepinephrine deactivate the prefrontal cortex?

Authors:  Paul J Fitzgerald
Journal:  Psychopharmacology (Berl)       Date:  2010-04-13       Impact factor: 4.530

Review 3.  Adrenergic pharmacology and cognition: focus on the prefrontal cortex.

Authors:  Brian P Ramos; Amy F T Arnsten
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

Review 4.  Psychostimulants as cognitive enhancers: the prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorder.

Authors:  Craig W Berridge; David M Devilbiss
Journal:  Biol Psychiatry       Date:  2010-09-26       Impact factor: 13.382

5.  Pharmacological analysis of alpha(2)-adrenoceptor subtypes mediating analgesic, anti-inflammatory and gastroprotective actions.

Authors:  K Gyires; Z S Zádori; N Shujaa; M Al-Khrasani; B Pap; M M Mózes; P Mátyus
Journal:  Inflammopharmacology       Date:  2009-06-13       Impact factor: 4.473

6.  Desipramine attenuates working memory impairments induced by partial loss of catecholamines in the rat medial prefrontal cortex.

Authors:  S M Clinton; I L Sucharski; J M Finlay
Journal:  Psychopharmacology (Berl)       Date:  2005-11-24       Impact factor: 4.530

7.  Modulation of Monoaminergic Systems by Antidepressants in the Frontal Cortex of Rats After Chronic Mild Stress Exposure.

Authors:  David Martín-Hernández; Marta P Pereira; Hiram Tendilla-Beltrán; José L M Madrigal; Borja García-Bueno; Juan C Leza; Javier R Caso
Journal:  Mol Neurobiol       Date:  2019-05-03       Impact factor: 5.590

8.  Noradrenergic modulation of risk/reward decision making.

Authors:  David R Montes; Colin M Stopper; Stan B Floresco
Journal:  Psychopharmacology (Berl)       Date:  2015-03-13       Impact factor: 4.530

9.  Lack of effects of guanfacine on executive and memory functions in healthy male volunteers.

Authors:  Ulrich Müller; Luke Clark; Minh L Lam; Rebecca M Moore; C Louise Murphy; Nicola K Richmond; Ranbir S Sandhu; Ingrid A Wilkins; David K Menon; Barbara J Sahakian; Trevor W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

10.  Heterozygous alpha 2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists.

Authors:  Christopher M Tan; Matthew H Wilson; Leigh B MacMillan; Brian K Kobilka; Lee E Limbird
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.